Key facts
- EtiraRx’s last known valuation is $45.0M (Jun 2025).
- It has raised $7.2M across 3 recorded rounds; the latest was Seed Round ($2.3M) in Apr 2026.
- Notable investors include National Cancer Institute.
- EtiraRx has filed 2 Form Ds with the SEC since 2023, most recently Jun 2025 ($2.4M sold to 3 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for EtiraRx
Funding rounds
3 roundsAbout EtiraRx
Operator of a biopharma research company intended to develop products to overcome tumor heterogeneity. The company advances novel cancer therapeutics, validating molecular drivers of cancers to lead a systemic evaluation of mechanisms of therapy resistance and to the development of novel therapeutics to treat cancers, enabling patients to plan for a future with previously untreatable cancers.
- Sector
- Healthcare
- HQ
- Dallas, TX, United States
- Founded
- 2018
- Employees
- 5
- Website
- etira.life/
- Ownership
- Privately Held (backing)
EtiraRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EtiraRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EtiraRx in its N-PORT filings yet. We sweep new filings monthly.